In summary, targeting the SIRT1-ZKSCAN3 axis or TFEB activation, combined with lysosomal-enhancing compounds (e.g., HEP14, LH2-051) and autophagy-targeting technologies (ATTEC/AUTAC), may provide multiple strategies for PD treatment, but the precise regulatory mechanisms of ZKSCAN3 need to be explored in depth [115]. Here, ZKSCAN3 is linked to Parkinson disease.